Kawaldip Sehmi, CEO of the International Alliance of Patients’ Organizations (IAPO), answers 5 questions on why the Essential Medicines List is important for patients. IAPO is a United Kingdom-based alliance of 276 member organisations from 71 countries representing 50 disease areas, and working in collaboration with civil society, UN agencies and the healthcare industry. Sehmi holds a Masters in Public Health from the London School of Hygiene and Tropical Medicine, and has previously served as Director of the Global Health Inequalities Programme and as Chairman of the European Network of Quitlines. This article is republished from “Global Health Matters,” a blog of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

IFPMA: What does the addition of new medicines on the 2019 Essential Medicines List (EML) update mean for patients?

Sehmi: The inclusion of any medicine, including innovative and specialty medicines, on the World Health Organization’s Essential Medicines List is good news: it should increase patient access to new treatment options, including to the latest innovative generics and biosimilar medicines. But this will only happen if the necessary steps are taken in each and every country to support delivery and uptake of these medicines. Getting a medicine on the list is an important but relatively tiny first step.

Countries need to strengthen their health systems and work with stakeholders, including patients, public and private funders of health systems, to ensure that sustained funding is available and that the health system infrastructure is robust and resilient if they are to safeguard the effective delivery of essential medicines to the patients and the community.

Even so, it is positive to see that more and more medicines are being included with each EML update, thus keeping abreast of medical innovation while recognizing that there are still unmet medical needs and increasing societal expectations, with more treatments added in areas such as Hepatitis C and Cancer.

IFPMA: How is the EML useful for patient representatives in your advocacy efforts?

Sehmi: There is a sea change in healthcare policy and decision-making as patients are increasingly being asked to support healthcare service development through experience-based co-design and co-creation partnerships. Expert-patients’ engagement on national essential medicines lists is slow to catch up with this approach.

It is important to have the patient perspectives on essential medicines lists. EML is just the tip of a huge healthcare infrastructure, workforce and resources iceberg. By just concentrating on the EML is like applying a sticky plaster to a compound fracture within the healthcare body.

However, the List is an important guide to what medicines should be available anywhere at any time – these should be seen as the bare minimum that any health system should be able to deliver. It should not become a box-ticking exercise, a bare minimum standard, the delivery of which absolves the State’s obligation to do much better. But, at the end of the day, the patient-physician partnership must be able to decide what is the most appropriate treatment for patients. For patient organizations, one idea is that the EML can be used along with individual country medicines lists to advocate for ‘missing’ treatments.

They can also benchmark their own country list with those used by neighboring countries, or countries with similar medical needs/health systems. We will be informing, educating and developing capacity within patient organizations to work towards this partnership-based approach now that the new list has been released. We need to do more work post-launch of EMLs.

IFPMA: What do you mean by doing more on “post-launch” of EML?

Sehmi: This year we are going to be marking the first World Patient Safety Day [17 September]. Medication safety is a central pillar in the WHO Director General’s global action on patient safety. When new medicines are included on the list, it is crucial that clear guidance be given to patients and health professionals on how they should be properly utilized (i.e., treatment guidelines, safe medication practices) and any necessary supporting systems, such as disease surveillance systems/registries, pharmacovigilance systems, diagnosis, patient monitoring, adherence, and management of comorbidities. Proper utilization of medicines is an issue very close to my heart and at the core of IAPO’s work. Unsafe medication practices and medication errors have become a global public health problem. The number of patients either injured, disabled or killed while accessing unsafe healthcare has become a huge global concern.

As one patient advocate said at the 72nd World Health Assembly: “In my country, people are afraid to go to hospitals as they think they will come out in a coffin or with a severe disability. Hospitals and healthcare services stand the risk of being empty if the community does not trust them.” I’m therefore delighted that the WHO Member States from all 194 countries endorsed the establishment of a World Patient Safety Day to be marked annually on 17 September and officially included on the WHO list of health dates.

IFPMA: WHO’s Report on Pricing of cancer medicines and its impacts released last year makes considerations about different pricing approaches to cancer medicines listed on the EML. What is IAPO’s view on this topic?

Sehmi: Ultimately, every patient must be able to access and afford the healthcare services they need – this is also one of the five principles outlined in IAPO’s Declaration on Patient Centred Healthcare. Our vision is that the needs of patients are placed at the center of all healthcare decision-making and, equally importantly, that patients have a direct role as partners in all matters from policy to individual choices. I think we all agree that there is no point in innovation if people cannot benefit from it.

But, equally, we should not lose sight of the fact that many medicines such as antibiotics, malaria treatments and statins, albeit relatively cheap, still do not reach patients who need them. For example, all the basic hypertension medicines are generic, inexpensive, safe and effective; they have been used in high income countries for more than half a century, but they are still not being used routinely in low income countries. In the case of oncology medicines, because of the complexities associated with cancer treatment, issues with supply chain integrity, insufficient health workers, low capacity for diagnosis and overall infrastructure limitations have to be part of the debate on access, along with pricing.

IFPMA: Looking ahead, what would you like to see in the next EML update?

Sehmi: A multi-stakeholder approach to the next EML update is key, starting with greater patient engagement and participation. Engaging patients in health policy decision-making is essential in order to ensure that policies adequately reflect patient and caregiver needs, preferences and capabilities. It is also important that the processes around the EML are open, inclusive and impartial. Deliberations of the advisory working groups established to advise the Expert Committee would be significantly improved with a wider membership, including patient organizations, National Regulatory Agencies, and NSAs, as official interlocutors with the WHO. Especially for innovative medicines, involving regulators in the discussion is key, as regulators are the ones reviewing the most detailed data regarding safety and efficacy of these medicines.

Image Credits: UNICEF/Noorani, Kawaldip Sehmi.

WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems.

The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects both the rapid pace of cancer drug research – as well as the growing need to respond to the worldwide increase in cancers and other non-communicable diseases.

In another long-awaited development, WHO also promoted the drug mifepristone-misoprostol for induced abortions from a complementary list to a more select core list, which together comprise over 450 essential medicines. However, it preserved a footnote saying that the drug should be used “where permitted under national law and where culturally acceptable,” which WHO’s Department of Reproductive Health and Research, backed by the United Nations Population Fund and numerous civil society groups, had requested be removed. However, WHO’s Director General Dr Tedros Adhanom Ghebreyesus ultimately decided to retain the longstanding nod to national and cultural norms, sources told Health Policy Watch.

In a press release, issued Tuesday, WHO said that improved survival rates were a key criteria for including the new cancer therapies as “essential medicines” – even if some of the treatments are costly.

“The inclusion in this list of some of the newest and most advanced cancer drugs is a strong statement that everyone deserves access to these life-saving medicines, not just those who can afford them,” said WHO’s Dr Tedros in the press release.

The new cancer therapies included two recently developed immunotherapies (nivolumab and pembrolizumab) “that have delivered up to 50% survival rates for advanced melanoma, a cancer that until recently was incurable,” the WHO release said. The therapies are produced by Bristol-Myers Squibb and Merck & Co.

Other new cancer drugs included Roche’s erliotinib treatment for lung cancer, which the report said demonstrated survival benefits similar to chemotherapy and improved quality of life. Jannsen Biotech’s abiraterone was included for treatment of patients with metastatic prostate cancer, following a request by the civil society organization Knowledge Ecology International (KEI). Other new treatments also were included for leukaemia and multiple myelomas.

The publication of the long-awaited update unleashed a wave of reaction from civil society, while sending a ripple through the pharma industry, as winners and losing drug candidates were examined and evaluated.

In South Africa, a coalition of nearly 45 patient advocacy groups said the WHO announcement offers new Health Minister Dr Zwelini Mkhize an “historic opportunity” to save lives by increasing access to one of the new drugs for multiple myeloma on the list, lenalidomide.

“Currently, the majority of cancer patients in South Africa who could benefit from lenalidomide cannot access it due to its prohibitively high cost – depriving many people of a chance at life,” said Salomé Meyer, from the Cancer Alliance in a blog posted online. In South Africa more than 400 new cases of multiple myeloma – a blood cancer of the plasma cells of bone marrow – are reported annually.

Other civil society advocates, however, said that WHO did not go far enough in embracing other cancer drugs that can improve survival rates for people with metastasised cancers.

KEI’s Director James Love told Health Policy Watch that two such breast cancer drugs, pertuzumab and trastuzumab–emtansine [TDM1], supported by KEI for inclusion into the list, didn’t make it, despite what he described as “robust evidence of efficacy.”

“What you now have is a list that has some effective and expensive drugs and not others, with a bias against metastasized cancers,” said Love of of the two breast cancer drugs; KEI had itself proposed inclusion of the trastuzumab-emtansine [TDM1] combination.

The WHO Executive Summary of the Essential Medicines List, on the other hand, said that the Committee had postponed inclusion of the these two breast cancer drugs pending further analysis, because the “large overall survival benefit” of pertuzumab found in one trial of women with metastasized cancers had not been seen in other trials, and for TDM1, alternative options are available on the list.

Dr Nicola Magrini, Secretary of the Essential Medicines List Expert Committee, noted that the new list is growing “rapidly and convincingly” with respect to cancer treatments – and health systems will face serious challenges just in responding to the new cancer drugs that have already been added to the list.

The WHO Expert Committee has also proposed a larger scientific and technical group meeting next year, together with countries and civil society, to discuss current challenges in providing cancer treatments and programs that meet the “expected EML [Essential Medicines List] standards, which are pretty high now,” he said.

New High-Priced Cancer Drugs

Indeed, efficacy is not the only issue involved in the debate over cancer drugs. Another key factor is pricing. As the Executive Summary notes, some of the cancer drugs chosen for inclusion are “high-priced cancer medicines.”

Love of KEI said that some of the rejected cancer drugs also would have introduced competition to drive down prices. He noted that the decision to exclude enzalutamide for treatment of prostate cancer ignores the pricing benefits that its inclusion would generate through competition with abiraterone, a drug that was accepted, but that carries a very high price.

Love said that exclusion of enzalutamide also could undermine efforts such as those by students at UCLA to convince the university to drop a patent suit in India against production of generic versions of the patented drug, marketed as Xtandi. Generic production would dramatically lower the price of enzalutamide, which currently costs around US$ 5,000 a month in India.

Love also noted that since enzalutamide is a monotherapy with smaller active ingredient (API) requirements than abiraterone, it would eventually become much cheaper to manufacture, making it a good option in terms of both efficacy and pricing in the long-term.

See below or here for details on the new cancer drugs added to the Essential Medicines List.

First All-Oral Drug for Sleeping Sickness

The latest Essential Medicines List also includes the first all-oral treatment for sleeping sickness, fexinidazole, an important milestone in the treatment of this neglected, and usually fatal, disease.

Registered by Sanofi and developed in clinical trials led by the Drug for Neglected Diseases initiative (DNDi), fexinidazole is used to treat the first and second stages of sleeping sickness, also known as Human African Trypanosomiasis, transmitted by the bite of a tsetse fly.

“65 million people, who live mainly in rural parts of East, West and Central Africa, are at risk of contracting sleeping sickness,” DNDi said in a statement.

Inclusion of the first all-oral drug in the Essential Medicines List “will spur governments in endemic countries to include fexinidazole in their treatment guidelines,” said Dr Nathalie Strub-Wourgaft, DNDi’s Director of Neglected Tropical Diseases, in the statement. “Inclusion of fexinidazole is also a further sign of WHO and Sanofi’s commitment to ensuring swift deployment of this paradigm-changing treatment.”

Insulin Analogues Not Included

During the WHO Expert Committee on the Selection and Use of Essential Medicines meeting in April of this year, debates were heated over how to address the rising cost of insulin, a life-saving essential medicine that has been available for nearly 100 years.

Some proposed for the inclusion of insulin analogues, an altered form of human insulin, to increase competition, but others strongly opposed this, noting that the high cost of insulin analogues – 8-11 times that of insulin – could actually drive insulin prices up.

The Committee ultimately decided not to include insulin analogues in the list, recognising “the need for a wider understanding of the complexities of access to insulin and the current insulin market,” and recommending that “WHO prioritize the coordination of a series of actions to address the issues of insulin access and affordability,” according to the Executive Summary.

“In the absence of other coordinated actions, the Committee considered that the inclusion of insulin analogues for adults on the EML [Essential Medicines List] would be inadequate to address the underlying issues of poor access and affordability of insulins,” it said.

The Committee’s decision was welcomed in a press release Wednesday by Health Action International (HAI), citing its recent study showing that analogue insulin can be as much as six times more expensive than human insulin, which is on the EML, and there is no independent evidence showing that the analogues are more cost-effective.

“A decision to include analogue insulins in the EML would increase pressure on national governments to purchase these far higher priced insulins. In low- and middle-income countries, where health systems budgets are already stretched; this would have disastrous consequences for people in need of insulin,” said Dr Margaret Ewen, co-lead of the HAI study in the statement, adding. “When the price of long-acting analogue insulin is lowered to an affordable level for governments and individuals, we would welcome a thorough evaluation on its value on the EML.”

Abortion Drug Moved to Core List, No Longer Requires Close Supervision

The drug combination mifepristone–misoprostol, used to end pregnancies that are less than 10 weeks along, was recommended by the Expert Committee to be moved from the complementary to the more select core list of medicines, and for the two drugs to be co-packaged.

The Committee further recommended the removal of the note accompanying the listing that the drug “Requires close medical supervision,” explaining in the Executive Summary that this is “based on the evidence presented that close medical supervision is not required for its safe and effective use.”

The Committee, however, noted that “its mandate did not extend to providing advice regarding the statement ‘Where permitted under national law and where culturally appropriate.’” So ultimately the decision to preserve the note was made by the WHO Director General.

Recommendations on Improving Access to and Affordability of Essential Medicines

In the Executive Summary, the Committee noted that throughout its April meeting to review and update the Essential Medicines List, issues of access to and affordability of the essential medicines was a core theme, particularly in the context of the rising cost of insulin and the high prices for the newly added cancer drugs. It further noted that this issue of affordability applies both to health systems and to patients.

While it acknowledged the “limited role of WHO in price setting at country level,” it “identified several different actions that could contribute to making some of the recently listed essential medicines more affordable at country level,” which include:

  • A wider adoption of biosimilars, which are the equivalent of less expensive generics for biologically-based drugs;
  • Expanding the remit of the Medicines Patent Pool, which negotiates with patent holders for licences of priority drugs to so as to make them available to low- and middle-income countries;
  • Expand the role of pooled procurement/tendering of drugs;
  • Use of patent flexibilities [available for health products], in the 1995 World Trade Organization (WTO) agreement on Trade Related Aspects of International Property Rights (TRIPS);
  • Other existing instruments, such as competition law;

Elaine Fletcher and David Branigan wrote this story.

Image Credits: WHO.

Nairobi, Kenya – The World Health Organization has commended efforts by the government of Uganda for keeping the deadly Ebola virus from spreading eastwards into the country from the Democratic Republic of the Congo (DRC), where a prolonged outbreak has claimed approximately 1,600 lives since last August.

The East African country has recorded only three confirmed cases of the disease since 11 June – when the first case was reported by WHO – linked to three people who had crossed the border into western Uganda from the DRC.

Another three suspected cases were being treated at a hospital near the DRC border, where health-workers have concentrated treatment facilities so as to contain the spread of the disease farther east in Uganda and the broader East Africa region.

Surveillance for ebola virus disease at the border between DR Congo and Uganda. Photo: WHO/Matt Taylor

The ability to check the spread of the highly contagious virus with a 68% fatality rate has so far been enabled by a good disease surveillance system managed by well-trained teams of health workers, according to Matshidiso Moeti, WHO Regional Director for Africa. Strong community-backed surveillance has also been critical, said Uganda’s Health Minister Jane Ruth Aceng.

“I commend Uganda for its quick response to the Ebola outbreak,” said Moeti to UN TV, when she toured western Uganda near the DRC border late last month (25-26 June). “I spoke with health authorities who told me how the training they had received in detecting the disease” enabled them to be “on high alert for patients with any signs of infection. They were able to move swiftly when the first Ebola cases arrived in their health facility,” she said, according to a WHO news release.

Uganda and the DR Congo share a porous 900 kilometre border – running through fertile and mineral-rich jungles. The rough terrain makes control over civilian crossing challenging. And on the DRC side, armed militias that oppose the DRC central government operate with relative impunity, particularly in the areas of Kivu. Nearby, Rwanda and Burundi also share a significant border with DRC, making Ebola surveillance by neighbouring countries even more important for the broader region.

Rapid Health Sector Mobilization & Ring Vaccination Strategy

Since the outbreak was declared in Uganda in early June, 1,063 ‘high risk individuals’ have been vaccinated Moeti said, adding that vaccination of contacts and contacts of contacts, a strategy known as ‘ring vaccination’, has shown good results in the DRC, and previously in other countries of West Africa.

The ring vaccination strategy has also contributed to the fact that there have been no new cases of Ebola in Uganda since 12 June, the latest WHO situation report noted.

Uganda has trained more than 9,000 of its health workers in detecting symptoms of Ebola, and has vaccinated nearly 5,000 workers against the disease.

Additionally more than 100 people who had contacts with people confirmed to have Ebola in Uganda are being monitored to enable a quick response if symptoms of the illness develop.

Community Leadership Key to Surveillance

With support from WHO and partners, another 16,000 community leaders and volunteers have been trained in remote border areas to help with disease surveillance; provide medical attention to potential patients; and alert authorities of suspected cases of infections, according to the WHO release.

The local teams, it said, serve as the “eyes and ears” of local and national emergency response systems supporting “surveillance, infection prevention and control, patient care, cross-border activities and coordination with communities.”

As a result of such community cooperation, all high-risk districts in the west of Uganda are able to screen people, identify suspect cases and trace the contacts of potential patients whenever needed, Uganda’s Health Minister Aceng said. “As of now we remain in a high alert, we will continue with our risk communication and sensitizing the population,” she said in a video of her visit to the field with Moeti.

She added that due to these efforts, there were no further known cases of Ebola transmission in Uganda presently, but monitoring efforts will continue until the pathogen was completely brought under control in the DRC.

In DRC, Community Mistrust & Unrest Continue to Fuel Ebola 

The 4 July situation report issued by the WHO indicated that in DRC, the epicentre of the outbreak, there were 285 new confirmed cases of Ebola during the 12 June – 2 July period, marking a trend of decreasing cases since the height of the epidemic in mid-April. A total of 2,369 cases have so far been recorded, with 2,275 confirmed cases resulting in 1,598 deaths, since the outbreak began in August of last year.

Source: WHO

The eastern DRC city of Butembo in DRC’s North Kivu region has borne the brunt of the outbreak, made worse by conflict and political instability that has seen health workers unable to reach patients, and in some cases lose their lives.

Teams of responders in the city of one million inhabitants have often faced community mistrust, fuelled by misinformation spread by politicians in the general elections that took place in late 2018.

Over the past six months, armed groups active in the area attacked health workers while looting and destroying Ebola treatment centres, during which frontline responders and security forces protecting them lost their lives, according to WHO reports.

WHO and Congolese authorities have been conducting awareness-raising activities for teams working in treatment and vaccination sites, aimed at helping to build community support and trust to ensure the safety of responders.

Unlike in the earlier outbreak in West Africa, the WHO and agencies involved in the current campaign have been relying heavily on vaccinations of people who have come into contact with victims, focusing on first and second degree contacts, demonstrating some success in containing the spread of the virus.

Despite this progress, the international NGO Médecins Sans Frontières (MSF/Doctors Without Borders) in its latest update lamented that attacks on health personnel have continued to date, which, coupled with inter-communal violence, contributed to the failure to end the outbreak – now more than ten months strong.

“Vaccination of contacts, contacts of contacts and frontline workers in Butembo and Katwa (the epicentre of the outbreak) is sometimes temporarily suspended because of threats to the safety of vaccination teams,” the organisation said.

However, it added that as a frontline entity involved in combating the disease, it now has the facilities, skills and scientific capacity to better manage the current outbreak, as compared to previous ones.

“We have new tools and improvements in the medical management of this epidemic, compared to previous Ebola epidemics, such as new developmental treatments; a vaccine that has given indications of being effective; Ebola treatment centres are more open and accessible for the families of patients; and provision of a higher level of supportive care,” it noted.

In Uganda, MSF declared that it will collaborate with health authorities “to improve the hygiene and infection prevention and control measures in Kagando and Bwera hospitals, where the confirmed Ebola cases were first admitted,” and would also “support the safe provision of care for medical needs unrelated to Ebola in these facilities, should the need arise.”

Image Credits: WHO/Matt Taylor, WHO.

[Republished from The Lancet]

Richard Horton, Editor-in-Chief of The Lancet, examines the issues around the pending appointment of a new executive director for UNAIDS, as well as the candidates for the post, following the May resignation of executive director Michel Sidibé. The selection process has fueled questions about who may now be best positioned to lead UNAIDS following a sexual harassment scandal that cast a shadow over the agency and its leadership – with some critics questioning whether it should continue as a separate institution altogether. Horton has led The Lancet since 1995, and has established the journal as a leading voice on cutting-edge health policy issues, ranging from antimicrobial resistance (AMR) to obesity and climate change. He is a recent recipient of the Roux Prize.

Richard Horton, Editor-in-Chief, The Lancet. Photo: ILO/A.Lwin

Who is best qualified to lead an organisation—UNAIDS—that has not only suffered severe reputational loss, but also faces threats to its continuing existence? UNAIDS is a jointly sponsored UN programme that has, in its own words, “led and inspired global, regional, national, and local leadership, innovation, and partnership to ultimately consign HIV to history”. But some observers believe this glorious history is just that—history. Rob Yates was recently appointed head of Chatham House’s Centre on Global Health Security. He wrote on Twitter last week that a new Executive Director of UNAIDS should have the “courage and ability to wind up the organisation and integrate it into @WHO”. Kul Gautam, a former Deputy Executive Director of UNICEF, argued that “now it’s time to question [UNAIDS] continuation”. Anthony Costello, most recently a Director at WHO, commented, “No one questions the need for a strong and distinct body for the HIV response. It’s whether UNAIDS would function better under the democratic accountability of the World Health Assembly which might have prevented its shameful recent history”. Laurie Garrett, a Pulitzer-Prize winning writer on global health, noted that those selecting the next Executive Director “MUST define clearly why the world needs UNAIDS & how it should fit in the global health landscape.” Is it time to choose a leader who will close down UNAIDS? Maybe one day. But not now. Predictions about the end of AIDS have been badly misjudged. According to the Global Burden of Disease Study, there were almost 1 million deaths from AIDS in 2017. Those deaths occur throughout the lifecourse, but the toll is especially severe among 15–49-year-olds (676 100 deaths). There are almost 37 million people worldwide living with HIV. And the incidence remains shockingly high—1·9 million people newly infected every year. Although the number of AIDS-related deaths is projected to fall, even by 2040 those deaths will still be unacceptably high (742 million, with a worst-case scenario of 2·3 million deaths). The AIDS epidemic is at a critical moment. Decelerating the political response by extinguishing UNAIDS now would be a catastrophic error.

Photo: UNAIDS/Sydelle Willow Smith

There are five candidates: Salim Abdool Karim (an infectious diseases epidemiologist and Director of the Centre for the AIDS Programme of Research in South Africa); Sani Aliyu (physician, infectious diseases expert, and Director-General of Nigeria’s National Agency for the Control of AIDS); Chris Beyrer (physician, HIV specialist, former President of the International AIDS Society, and Professor of Public Health and Human Rights at Johns Hopkins Bloomberg School of Public Health); Winnie Byanyima (engineer, politician, diplomat, and now Executive Director of Oxfam International); and Bernard Haufiku (physician and Namibia’s former Minister of Health and Social Services). Each candidate has strengths. Aliyu spearheaded Nigeria’s AIDS response under difficult political circumstances. Haufiku has ministerial experience. Byanyima knows how to run a complex global organisation. Karim is a highly respected HIV scientist whose work has transformed clinical practice. And Beyrer, whose partner died of AIDS in 1991, successfully uses human-rights approaches to protect and advance the health of marginalised communities in Asia, Africa, Latin America, Russia, and the US. There are disappointments. Only one woman? No forum for public debate and scrutiny? Appointment not election?

The next Executive Director of UNAIDS must fulfil five criteria. First, s/he must have the personal integrity to restore trust and credibility to a damaged organisation—and to give governments confidence to invest in the AIDS response. Second, s/he must have proven scientific understanding of the AIDS epidemic in order to be able to use evidence as a platform for political advocacy. Third, s/he must have demonstrable ability to represent and engage with civil society. Fourth, s/he must be able to point to their commitment to key vulnerable populations. And finally, s/he must be able to show transformational leadership of a large organisation. The Programme Coordinating Board of UNAIDS met in Geneva last week and “commended the strong competencies of all short-listed candidates”. After interviews, a Committee of Cosponsoring Organisations will deliver no more than three names to the UN Secretary-General, António Guterres. It is no exaggeration to say that his choice may determine the future fate of the AIDS epidemic.

Salim Abdool Karim, Director of the Centre for the AIDS Programme of Research in South Africa. Photo: Rajesh Jantilal/AFP/Getty Images
Sani Aliyu, Director-General of Nigeria’s National Agency for the Control of AIDS. Photo: Sani Aliyu
Chris Beyrer, Professor of Public Health and Human Rights at Johns Hopkins Bloomberg School of Public Health. Photo: Rajesh Jantilal/AFP/Getty Images
Winnie Byanyima, Executive Director of Oxfam International. Photo: Franke Tsang/South China Morning Post/Getty Images
Bernard Haufiku, Namibia’s former Minister of Health and Social Services. Photo: UN Photo/Rick Bajornas

 

 

 

 

 

 

 

 

 

Republished with permission from The Lancet: https://doi.org/10.1016/S0140-6736(19)31563-6. Click here, for more information about Richard Horton and The Lancet.

Image Credits: UNAIDS/Sydelle Willow Smith, ILO/A.Lwin, Rajesh Jantilal/AFP/Getty Images, Sani Aliyu, Franke Tsang/South China Morning Post/Getty Images, UN Photo/Rick Bajornas.

Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council.

This time the debate is around ways to “delink” incentives for the research and development of new medicines from patent systems that “reward” companies or institutions investing in the drug’s development with a legal monopoly over sales of the end-product for years to come.

The sensitive “delinkage” issue is part of a draft Human Rights Council (HRC) resolution on “Access to medicines and vaccines in the context of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health,” under consideration at this month’s session in Geneva.

Human Right Council. Photo: UN/Jean-Marc Ferré

“Delinkage” has become a mantra for many civil society and patient advocacy groups, as well as some governments, which perceive exclusive patent rights as a key driver in rising drug prices, limiting access to new treatments. The term broadly refers to alternative incentives or rewards that reduce reliance on patents as a means of financing R&D, yielding products that are cheaper and more readily available.

The draft HRC resolution on medicines access, due for its final review on 11 July, is backed by a core group of countries including Brazil, China, Egypt, India, Indonesia, Senegal, South Africa and Thailand. Representatives of that group point out that the recently contested delinkage paragraph was part of an already-approved 2016 version of the same resolution, and is merely being reaffirmed again in this year’s updated draft, which now has 27 co-sponsors in all.

“The Human Rights Council brings this resolution up every three years, because it is viewed as worthy in this context, to have a human rights perspective on access to medicines,” said Brazil’s representative Clara Solon in a public HRC consultation Tuesday.

The text calls upon countries “to continue to collaborate, as appropriate, on models and approaches that support the delinkage of the cost of new research and development from the prices of medicines, vaccines and diagnostics for diseases that predominantly affect developing countries, including emerging and neglected tropical diseases, so as to ensure their sustained accessibility, affordability and availability and to ensure access to treatment for all those in need.”

Two other paragraphs [8,9] ”encourage” governments, international organizations, NGOs, researchers and the private sector to pursue alternative R&D incentives, in terms such as the following:

  • “improved existing and alternative frameworks to adequately reward innovation, pricing and affordability of health products;” and
  • “to redouble efforts to achieve a continuous supply of quality, safe, effective and affordable health products through research and development that meets public health needs, for the efficient application and management of intellectual property standards, to carry out evidence-based selection of health products and seek fair and affordable pricing.”

Delinkage Supporters and Critics

Support for “delinkage” principles has been growing over the past decade, led by figures ranging from US Presidential hopeful Bernie Sanders to Nobel Prize winning economist Joseph Stiglitz and Bernard Pecoul of the Geneva-based Drugs for Neglected Disease Initiative. Countries supporting the idea have included India, The Netherlands, and the Group of 77, representing some 134 developing nations. Some private sector voices, notably former GlaxoSmithKline CEO, Sir Andrew Witty, have also expressed support for innovative ways to fund R&D.

The advocates assert that the current R&D system, based around granting exclusive patent rights for new drugs, is breaking down. Newly patented drugs that are coming onto the market are increasingly priced in a range that stretches the budgets of high-income countries, while leaving middle- and low-income countries out of the loop altogether.

The problem is particularly acute for drugs treating non-communicable diseases such as cancer, where new therapies can carry a $US 100,000+ annual price tag. And particularly if public funds or tax breaks are invested in drug R&D, then rewards other than exclusive patent monopolies should be considered for the final drug products, advocates assert.

“Access will always be unequal without the delinkage of R&D costs from the prices of drugs, vaccines, cell and gene therapies, diagnostic tests and other health technologies and services,” remarked Thiru Balasubramanian, of Knowledge Ecology International (KEI), in an interview. One of the groups that participated in last week’s HRC consultations, KEI has been a flagbearer of the delinkage concept.

At the same time some key developed countries, including Switzerland, Japan, Australia, and the European Union representative at the HRC, contend that existing patent systems remain the backbone stimulating R&D investments, and that the HRC resolution treads too far into territory outside of its traditional domain. They have asked for deletions or major changes in the paragraphs that reference “delinkage” as well as references to alternative R&D incentives.

“Delinkage is stated too broadly. As supporters of the global IP system [for medicine patents], we want to make sure that it keeps performing, while finding solutions in areas where it is not working. But we are very worried about taking a one-size-fits-all approach,” Nora Kronig, head of International Affairs at the Swiss Federal Office of Public Health, told Health Policy Watch.

“Looking at access to medicines broadly, there are a lot of elements that come into the chain. For instance, if you don’t have robust regulatory systems people can’t get medicines either. It is also untrue to talk about market failure with respect to the whole access to medicines issue,” she added.

While critics are increasingly adamant that the current system is cracking, “saying that that there is a global market failure on access to medicines generally is not accurate,” argues Kronig. “We are fully open to discuss possibilities where things are not working to find solutions to improve access to medical products, but what we are very worried about is to undermine a largely functional system to offset unquestioned distortions in sub-sectors of the markets for medicines.”

Informal Consultations on the Draft Resolution

At Tuesday’s informal consultations on the draft, other countries expressed concerns that the Human Rights Council may be duplicating work already being carried out by the World Health Organization and the World Health Assembly body of WHO member states.

“We share concerns about how we are use these very overstretched platforms,” said Canada’s delegate. “While still recognizing there is a role for human rights, … we would like to refrain from re-negotiating thoughts and technical issues that are already being discussed in other fora such as WHO and WHA.”

The final text of the HRC draft resolution, obtained by Health Policy Watch, reflects slight modifications in the disputed paragraphs, although terms like “delinkage” remain along with reference to alternative incentives for drug R&D.

Besides the core group, other co-sponsors of the resolution, so far, include HRC members from: Bangladesh, Iraq, Peru, Philippines, Qatar, Saudi Arabia, Tunisia, and Uruguay. UN member states and observers that are not officially members of the HRC can still co-sponsor HRC resolutions, and such supporters include: Algeria, Bolivia, Ecuador, Eswatini, Ethiopia, Haiti, Kuwait, Mongolia, Turkey, the United Arab Emirates and Palestine.

Talks with other countries will continue up until next Thursday, when the final resolution is formally reviewed by the HRC. But the essence of the three contested paragraphs would not change or be removed, core sponsors affirmed.

“The resolution has one paragraph mentioning de-linkage, and some European countries don’t like this,” said one delegate, who asked not to be named.

“But the resolution is not about delinkage, it touches on many aspects of access to medicine, including delinkage and alternative frameworks [for R&D], but we also talk about rights to health, health literacy, many other issues. It is very broad text.”

“We are not planning to make more changes in the text, but we will work very hard to add more cosponsors as well as to try to avoid public objections to the final text,” the delegate added. “But if it comes to it, we will have a vote.”

Image Credits: UN Photo / Jean-Marc Ferré, CDDEP.

The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database.

The open letter by the European Commission (EC), the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) reminded sponsors that according to a 2012 EC guideline, clinical trial summary results are required to be published in the EU Clinical Trials Database, EudraCT, and that publishing these results is their direct responsibility.

“Transparency and public access to clinical trial results, whether positive or negative, are fundamental for the protection and promotion of public health,” the EMA said in a press release.

“In addition, for those medicines which are placed on the market or used in further clinical trials, it allows patients and healthcare professionals, or any other citizen, to find out more information about medicines they might be taking or prescribing,” it said.

The letter noted that out of the 27,093 completed clinical trials in the EudraCT database, 68.2 percent are in compliance with the EU publication rules and 31.8 percent have missing results, which the letter identified as “an encouraging trend.”

However, it added that “there is still significant progress to be made,” citing that reporting compliance for non-commercial sponsors is low at 23.6 percent, compared to that of commercial sponsors at 77.2 percent.

The letter particularly encouraged academic and other non-commercial sponsors “to post the results of their trials in EudraCT in order to maximise their valuable contribution to meet public health needs and to advance clinical research especially where commercial interest is weaker.”

“Underreporting in general and selective reporting of trials with positive outcome may lead to potentially avoidable redundancies in the conduct of clinical trials and compromise the economic and scientific efficiency of clinical research,” it warned. “In addition, unreported clinical trials with unfavourable outcome can have negative public health implications.”

Image Credits: European Medicines Agency.

The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR).

Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect people in countries across income levels; addressing the growing threat of AMR will be key to achieving universal health coverage (UHC) and the Sustainable Development Goals (SDGs), a GARDP press release explained.

“We are in a race against time to develop new antibiotics and make them accessible to the millions of people who need them. GARDP’s remarkable progress over the last three years in building strong partnerships and a talented team positions it well to meet this ambitious new goal,” said GARDP’s Chair of the Board, Professor Ramanan Laxminarayan, quoted in the release.

“WHO strongly welcomes the progress of GARDP to date and its new ambitious ‘5 BY 25’ goal which complements WHO’s Global Action Plan on AMR. We call on all key actors to support and collaborate with GARDP in line with the UN Interagency Coordination Group on AMR,” said Dr Hanan H. Balkhy, Assistant Director-General for AMR Division at WHO, in the release.

This “5 BY 25” strategy is part of GARDP’s new business plan, which was recently approved by the GARDP Board and will be launched at the World Health Summit in October. The strategy is detailed in a recent webinar by Dr Manica Balasegaram, GARDP Executive Director.

Calling on the support of member states, philanthropic and other global organisations, GARDP aims to develop five new treatments that will focus on the priority pathogens identified by the World Health Organization, along with current unmet needs for diseases and key populations. GARDP aims to achieve this by “developing assets in late stage clinical development and ensuring access,” the GARDP website explains.

The five categories of WHO priority pathogens include:

  • Carbapenem-resistant (CRAB): A. baumannii
  • Carbapenem-resistant (CRE): Enterobacteriaceae
  • Sexually transmitted infections
  • Children (paediatric antibiotics)
  • Neonatal sepsis

“Alarming levels of resistance are now reported in countries of all income levels, with the result that hundreds of thousands of newborns are dying of untreatable sepsis, and patients are suffering from gonorrhoea and serious bacterial infections that do not respond to any available antibiotics,” the release said. “While AMR has the highest burden in low to middle income countries, high income countries are also greatly affected.”

Image Credits: GARDP.

Globally, political resistance to assertive climate action remains an enormous barrier to change, despite mounting evidence about the impacts of climate change on people’s well-being and health, said Angel Gurria, secretary general of the Organisation of Economic Co-operation and Development (OECD), before an audience of several hundred people in Geneva today.

Reframing the climate debate in more people-centered terms is critical to overcoming the naysayers; so the OECD will publish a report on “Climate Change Mitigation through a Well-being Lens” ahead of the UN Climate Summit in September, said Gurria, speaking at Geneva’s Graduate Institute of International and Development Studies in the fourth of a series of biennial climate lectures.

As one recent example of political ambivalence, Gurria cited the convoluted language on climate that emerged out of last week’s G-20 meeting in Osaka Japan where: “G20 countries ‘agreed to disagree’ on committing to fully implement the Paris Agreement.”

Gurria was referring to the final G20 declaration, in which the United States reiterated its decision to withdraw from the Paris Agreement, while other G20 nations reaffirmed their commitment to its “full implementation,” although adding a politically-laden caveat: “reflecting common but differentiated responsibilities and respective capabilities, in the light of different national circumstances.”

Departing from his prepared remarks, Gurria offered a colourful description of the intense negotiations between the Group of 20 leaders of the world’s most industrialised nations over the final climate text.

“You cannot imagine how difficult it was,” he related. “We took it to the leaders, Macron, Merkel, Theresa May, Trump.” Referring to the urgent, direct consultations that took place between France, Germany, the United Kingdom, the USA and others over the final draft, he observed that: “It looked like a rugby scrump.”

“Without their participation we wouldn’t have had any language in the G20,” he said, adding: “And imagine if the G20 does not come out with some language about climate change. It’s like you are ignoring the single most important inter-generational responsibility that we have today, and you cannot even agree on the words you are going to produce. We came very close.”

Recent Trends Show Accelerated Emissions

In deeds, as well as in words, politicians are moving one step forward and two steps back, noted Gurria.

On the positive side, there have been a wave of commitments from some of the OECD‘s 36 member countries, as well as others, to combat climate change: “The UK just went 14 days without coal-fired power. Costa Rica is on track to become the world’s first carbon-neutral nation. New Zealand has banned new permits for offshore oil and gas exploration. Norway is dropping fossil fuel investments from its national pension fund, the world’s biggest wealth fund, to redirect funds towards renewables. The new Danish government has pledged to up its 2030 emissions reduction target from 40 percent to 70 percent of 1990 emissions levels, and to ban the sale of all new diesel and petrol cars from that year [2030].”

Yet, at the same time, he observed: “the United States is ramping up oil and gas production with fracking… [and] Canada is seeking to expand its carbon-intensive oil sands industry. Australia just approved the construction of a coal mine which could become the world’s largest. Mexico has announced plans for the construction of a new coal power plant and a large oil refinery. In Brazil, logging in the Amazon rain forest is accelerating at an alarming rate.”

Meanwhile, he added, “China and India continue to drive global growth in coal demand, with coal-fired power generation increasing strongly in both countries in 2018. Despite a significant drop in fossil-fuel subsidies, Indonesia plans to nearly double coal use by 2025.”

The latest OECD report on fossil fuel subsidies, released just last month, showed that public spending to support fossil fuels increased by 5 percent over 2016 levels to US$ 340 billion in 2017.

“We are giving hundreds of billions to fossil fuels,” Gurria observed. “And nearly 80 percent of energy-related carbon emissions in OECD and G20 economies are not yet priced at even a conservative estimate of climate costs.”

The net result is that after a three-year plateau between 2014-2016, energy-related carbon dioxide emissions are accelerating again, reaching unprecedented levels in 2018, according to the latest global data.

Climate Action Through A Human Well-Being Lens

Currently, the world is “treading a fine line” where rising temperatures could trigger dangerous “tipping points in the climate system,” beyond which climate change could go out of control and present scientific forecasts cannot predict the consequences, warned Gurria.

Already he said, “ocean acidification and warming is driving rapid and dramatic changes in marine ecosystems. Moreover, nearly one million species are threatened with extinction driven by our increasing demands for food and energy. We are now on the brink of the planet’s sixth major extinction. Our life support systems are at risk of failing.”

Against that dismal forecast, Gurria said that politicians need to “put people at the centre of climate action by looking at climate mitigation through a well-being lens.”

Doing so can create policy approaches that generate win-win outcomes, strengthening the case for early action.

Taking transport as a case in point, he observed that the “costs from a health perspective alone are considerable. The burden of air pollution from road transport in OECD countries and the BRICS [Brazil, Russia, India, China and South Africa] was around 3.2 million deaths and USD 5.1 trillion in 2015.”

Examined through “a well-being lens, we see that the transport sector should not aim at increasing physical movement but at enhancing accessibility, making it easier for everyone to reach destinations for goods, services, jobs and other activities,” he said, etching out an alternative vision of the future “where we don’t sit in our cars, but reallocate road space for all users and activities – walking, cycling, public transport and cars.”

Intergenerational Responsibility

Hearkening back to how the 1987 UN report “Our Common Future,” led by former Norwegian Prime Minister Gro Harlem Brundtland, was a milestone in defining the challenge of “sustainable development,” Gurria said that present-day political leaders owe it to the next generation to “reclaim our common future” by taking concrete actions soon.

Those should include a “meaningful” price on carbon, an “end to subsidised fossil fuels and a phase-out of coal,” he asserted.

“Human well-being is the ultimate goal of both environmental and developmental policies. If it doesn’t translate into well-being it is not worth the paper it is written on. Thirty years ago a lot of what the Brundtland report talked about was intuitive. Today we know more. A generation later this call for responsibility resonates even more.”

“Our failure to decisively act on climate today mortgages the prospects for our children to benefit from the climate conditions that have allowed us and mankind for the last 10,000 years to thrive… [T]hey may not have that privilege. The choices we make today determine what we will bequeath to our descendants.”

“Our children, youth, are angry; they have every right to be,” he said, recalling the wave of recent youth strikes and protest over climate change.

“We have already squandered precious time… and we are living the consequences of climate destruction. Our policies have to be made with our children’s future in mind.”

In a surprise appearance before the 2019 Congress of the International Council of Nurses, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that investing in a stronger nursing workforce is essential for achieving universal health coverage (UHC). He proposed that “every country bring one nurse and one midwife to the World Health Assembly next year,” as part of planned celebrations of the International Year of the Nurse and the Midwife, saying: “The world must hear their voices and their stories.”

Health workers are not a cost, they’re “an investment that pays a triple return for health, gender equality and economic growth,” Dr Tedros said, citing the 2016 United Nations High-Level Commission on Health Employment and Economic Growth.

“The world is facing a shortfall of 18 million health workers needed to achieve and sustain universal health coverage by 2030,” added the Director-General in his remarks Sunday before the Congress. Nurses and midwives make up half of this projected shortfall – a gap of 9 million professionals.

“Good move Dr Tedros. Women deliver health to 5 billion people and will deliver UHC – 70% health workers are women, majority nurses with critical role on front-lines [of] global health. Investing in female health workforce is smart move,” said Ann Keeling of Women in Global Health in a Tweet.

The WHO Director-General also noted that a first-ever WHO State of the World’s Nursing report will be published next year ahead of the WHA and during the International Year of the Nurse and Midwife, marking the 200th anniversary of the birth of Florence Nightingale, the founder of modern nursing. A State of the World’s Midwifery report will also be launched around the same time. The year will also cap off a three-year NursingNow! campaign (2018-2020), which was aimed at raising the status of nursing worldwide.

Photo: Global Fund to Fight AIDS, Tuberculosis and Malaria

The appearance by Dr Tedros at the five-day Congress in Singapore, which ended yesterday, underscores the emphasis that the World Health Organization is putting on health workers as a key component of UHC strategies.

“We simply cannot achieve universal health coverage and the health-related targets in the Sustainable Development Goals unless we empower and equip nurses and midwives, and harness their power,” said Dr Tedros in his remarks at the conference, adding that “any society with too few health workers is operating with one hand tied behind its back.”

“We can have the best medicines, the best diagnostics, the best hospitals and the best health insurance, but if we don’t have health workers delivering safe, effective, people-centred care, we don’t have a health system.”

The International Council of Nurses (ICN) is a federation of more than 130 national nurses’ associations representing the millions of nurses worldwide. The theme of its 2019 Congress (27 June – 1 July) was to explore “the many ways in which nurses work to achieve universal access to health, not only providing health care but also addressing the social determinants of health, such as education, gender equality, poverty, etc.”

ICN President Annette Kennedy said at the Congress that the WHO’s “goal of Health for All will only be achieved if there are enough properly trained nurses working at the right time and in the right place.” She added that “ICN will always strive to influence health, social, educational and economic policies to bring the best out of nurses and ensure they can provide the world with the care, treatment and comfort that only they can deliver.”

The WHO Director-General emphasised the importance of the WHO partnership with ICN, which celebrated its 120th anniversary this year, “on a range of issues, including primary health care, universal health coverage, quality of care, noncommunicable diseases, antimicrobial resistance, and more.”

Dr Tedros also referred to last week’s G20 leaders declaration, issued on 29 June at the close of the G20 meeting in Japan, which includes the commitment to “strengthen health systems, with a focus on quality, including through enhancing health workforce and human resources.”

“We must all hold the G20 leaders to the commitments they have made,” he said.

Image Credits: Global Fund to Fight AIDS, Tuberculosis and Malaria.

Sounding a note of ever-increasing urgency, United Nations Secretary General Antonio Guterres told ministers gathered at a Global Preparatory Meeting for the UN Climate Action Summit, in Abu Dhabi that “we are in a battle for our lives” with regards to climate change, which is happening at an even faster pace that what top scientists had predicted.

He called on governments worldwide to stop subsidising fossil fuels and building coal power plants; put a tax on carbon emissions; and shift to a green economy powered by renewable energy, in order to cut greenhouse emissions 45 percent by 2030 and achieve carbon neutrality by 2050. Scientists estimate such drastic cuts are needed to keep global warning to 1.5°C, and avert “a catastrophe for life as we know it’, said Guterres.

The two-day conference (30 June-1 July) included a first-ever global gathering of health and environment ministers to talk about the health threats from air pollution and climate-induced disasters. That meeting signaled growing political recognition of the intimate links between climate change and health, including deaths and injuries from extreme weather as well as a global toll of 7 million air pollution-related deaths annually.

Climate threats strike at no less than the fundamentals of life itself, said Guterres in his remarks at Sunday’s opening session.

“Climate disruption is happening now and it is happening to all of us,” said Guterres in his opening address Sunday before the meeting of ministers of climate, environment, health and energy from around the world. “Every week brings new climate-related devastation. Floods, drought, heatwaves, wildfires, superstorms.”

“It is progressing even faster than the world’s top scientists have predicted, and it is outpacing our efforts to address it. Climate change is running faster than what we are,” he said, calling for a “rapid and deep change in how we do business, generate power, build cities and feed the world.”

Guterres said solutions should include major global shifts in how energy systems are financed and taxed. “First, let’s shift taxes from salaries to carbon,” he said. “We should tax pollution, not people. Second, stop subsidizing fossil fuels. Taxpayers’ money should not be used to boost hurricanes, spread drought and heat waves, and melt glaciers. Third, stop building new coal plants by 2020. We need a green economy, not a grey economy. New infrastructure must be climate-smart and climate-friendly. And we must provide sustainable, clean and affordable energy for the more than 800 million people who still live without access to power.”

The two-day Climate Action meeting in Abu Dhabi aims to build political will for slashing emissions ahead of the 23 September UN Climate Summit in New York City, which will bring together heads of state to make firm commitments on climate change.

Statements by United Arab Emirates (UAE) officials and other organisers described the ministerial meeting as an important political platform to raise the visibility of issues ahead of the Summit.

Health and Environment Ministers Meet in Abu Dhabi

Along with meetings on energy, infrastructure and finance, the “health-climate nexus” was another featured element of the Abu Dhabi event as health and environment ministers sat down together today for the first time ever.

Rodolfo Lacy, OECD Director of Environment was quoted saying that it was a “historic moment”.

The meeting was organised in collaboration with the World Health Organization and the UAE’s Ministry of Health and Prevention as well as the Ministry of Climate Change and Environment.

Organisers said that the meeting aimed to (a) strengthen and endorse health-centered climate mitigation and adaptation initiatives and (b) demonstrate political commitment to dual strategies for climate and health issues.

Themes addressed included: air pollution and health risks; reducing morbidity and mortality from climate-induced disasters and extreme weather events; and financing for creative solutions that simultaneously address climate threats and benefit health, for instance by cleaning up air pollution, water contamination, and improving waste management.

The ministers also discussed how such solutions could be integrated in government policies and programs, including Nationally Determined Contributions (NDCs) which are a voluntary mechanism by which countries commit to climate mitigation actions under the 2015 Paris Agreement, as well as, National Adaptation Plans.

“Fighting climate change is the best investment ever; we can save 7 million lives a year,” Thani Al Zeyoudi, UAE Minister of Climate Change and Environment, was quoted on Twitter as saying, referring to the WHO estimate for lives lost from outdoor and household air pollution every year.

Image Credits: Rodolfo Lacy/OECD.